288.40 USD
↗ 3.60 (1.26%)PRE MARKET (AS OF 08:44 AM EDT)
Shares of ABBVIE INC. (ABBV) are trading at $288.40. The stock presents a mixed profile: our models indicate a Strong Buy for technical indicators, while underlying fundamentals flash a Sell. Notable factors include negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Oct 21, 2026.
Open?$284.75
High?$288.40
Low?$284.75
Prev. Close?$284.80
Volume?53.2K
Avg. Volume?4.8M
VWAP?$287.25
Rel. Volume?0.01x
Bid / Ask
Bid?$286.40 × 200
Ask?$287.80 × 100
Spread?$1.40
Midpoint?$287.10
Valuation & Ratios
Market Cap?503.3B
Shares Out?1.8B
Float?1.8B
Float %?100.0%
P/E Ratio?80.01
P/B Ratio?-84.80
EPS?$3.56
Dividend?2.38%
Ex-Dividend?N/A
News
Profile
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Themes
Employees
57.0K
Market Cap
503.3B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2012-12-10
Address
1 NORTH WAUKEGAN ROAD
NORTH CHICAGO, IL 60064
Phone: (847) 932-7900
NORTH CHICAGO, IL 60064
Phone: (847) 932-7900
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?77
Z-Score?64
Momentum?75
Short Sent.?88
Piotroski F-Score?6/9Mixed
Altman Z-Score?2.77Grey
Confidence?79%Moderate
Short InterestModerate
Short % of Float?0.92%Low
Short Interest?16.3M
Days to Cover?4.1
Free Float1.8B
Avg Daily Volume3.9M
Settlement Date2026-09-30
Financial Health
Current Ratio?0.81Weak
Quick Ratio?0.69Weak
Cash Ratio?0.16Low
Debt/Equity?-11.93Low
ValuationFAIRLY VALUEDvs 10 peers + S&P 500
Score56/100
P/E?80.0PRICEY▾
Peers33
S&P3
P/B?-84.80CHEAP▾
Peers100
S&P97
P/S?7.82HIGH▾
Peers36
S&P14
P/FCF?27.6FAIR▾
Peers40
S&P34
EV/EBITDA?19.2FAIR▾
Peers60
S&P29
EV/Sales?8.81HIGH▾
Peers36
S&P14
Returns & Efficiency
ROE?-106.0%WEAK▾
Peers11
S&P3
ROA?4.7%FAIR▾
Peers44
S&P42
Cash Flow & Enterprise
FCF?$18.2B
Enterprise Value?$567.5B
Fundamentals ratios updated end of day